Metformin/teneligliptin

Drug Profile

Metformin/teneligliptin

Alternative Names: Teneligliptin/metformin

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Biguanides; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2014 Preregistration for Type-2 diabetes mellitus in South Korea (PO, 1000mg/20mg)
  • 30 Nov 2014 Preregistration for Type-2 diabetes mellitus in South Korea (PO, 500mg/10mg)
  • 31 Oct 2014 Preregistration for Type-2 diabetes mellitus in South Korea (PO, 750mg/10mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top